LCN2 and chronic kidney disease: This is the third study from our group showing that FGF23 reduction in CKD using different approaches, consistently leads to improvement of cardiac morphology and function despite persistent kidney disease.1,2 Ours study also suggests that LCN2 may be involved in secondary outcomes associated with progressive CKD, including the development of heart disease.